Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy

NCT05696795 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05696795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2023
Completion date
April 23, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoidosis